Skip to main content
Hyung Chul Park on Muck Rack

Hyung Chul Park

As seen in: MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hyung Chul

Contact Hyung Chul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

|
By Wonsuk Shin, Hyung Chul Park, HyeJung Lee, A-Young Yang
| MDPI
4.1. Participants and Study Design This study was conducted at the Global Clinical Trials Center of the CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, with strict adherence to the key ethical principles outlined in the Declaration of Helsinki, the Good Clinical Practice Guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, and local laws and regulations.
Open in Who Shared Issue with article?

Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications

|
By Soon-Yong Kwon, Ji Hoon Bahk, Woo-Lam Jo, Hyung Chul Park
| MDPI
4. Discussion High-dose intravenous bisphosphonate treatment is inevitable in multiple myeloma patients due to its highly aggressive disease burden and poor survival (recent 5-year survival rate of about 50% [27,28]), despite its high risks of devastating skeletal complications of AFF and MRONJ.
Open in Who Shared Issue with article?
See all 2 articles